Outlook Therapeutics resubmits BLA for ONS-5010 (wet AMD) to FDA after Sept 2025 Type A meeting

Outlook Therapeutics, Inc.

Resubmitted BLA on Nov 3, 2025 for ONS-5010 (LYTENAVA) to treat wet AMD.
Resubmission follows FDA Type A meeting in Sept 2025; aims to resolve CRL issued Aug 2025.
CEO Bob Jahr says resubmission marks 'important step forward' for potential near-term U.S. approval.
Company accelerating commercial efforts in Europe while positioning for U.S. approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.